Cough Management in Children

Recommended Treatment

The American Academy of Pediatrics recommends honey as the first-line treatment for cough in children over 1 year old, as it provides more relief for cough symptoms than no treatment, diphenhydramine, or placebo 1, 2

Medications to AVOID

Over-the-counter cough and cold medicines should not be used in children as they have not been shown to make cough less severe or resolve sooner 1, 2
Codeine-containing medications must be avoided in children due to potential serious side effects including respiratory distress 1, 2
Antihistamines have minimal to no efficacy for cough relief in children and are associated with adverse events when combined with other OTC ingredients 1, 3

Important Safety Considerations

Never give honey to infants under 12 months of age due to risk of infant botulism 2

When to Seek Further Evaluation

Most acute coughs are self-limiting viral infections requiring only supportive care, but re-evaluate if cough persists beyond 2-4 weeks for emergence of specific etiological pointers 2, 3
All children with chronic cough require thorough clinical review using pediatric-specific cough management protocols 4, 5, 6
Chest radiograph and spirometry (if age-appropriate) should be obtained for children with chronic cough 5, 6

Common Pitfalls to Avoid

Using adult cough management approaches in pediatric patients 3
Prescribing OTC medications due to parental pressure despite lack of efficacy 1
Failure to re-evaluate children whose cough persists despite treatment 3
Empirical treatment for asthma, GERD, or upper airway cough syndrome without clinical features consistent with these conditions 4, 5, 7

Environmental Modifications

Evaluate and address tobacco smoke exposure and other environmental pollutants in all children with cough 3, 6
Assess parental expectations and concerns as part of the clinical consultation 5, 6

Dextrometorfano en Niños: Indicaciones y Recomendaciones

Recomendación Principal

La Academia Americana de Pediatría aconseja específicamente contra el uso de dextrometorfano para cualquier tipo de tos en niños, ya que las revisiones sistemáticas demuestran que los medicamentos para la tos de venta libre tienen poco o ningún beneficio en el control sintomático de la tos en niños 8, 9

Evidencia Contra el Uso en Pediatría

Las revisiones sistemáticas concluyen que los medicamentos para la tos de venta libre (incluyendo dextrometorfano) tienen poco o ningún beneficio en el control sintomático de la tos aguda en niños 8, 9
La Academia Americana de Pediatría ha emitido una advertencia específica contra el uso de dextrometorfano para tratar cualquier tipo de tos en población pediátrica 8, 9
El uso de medicamentos para la tos de venta libre se ha asociado con morbilidad significativa e incluso mortalidad en niños 8, 9
Los medicamentos de venta libre son causas comunes de ingestión no intencional en niños menores de 5 años 8, 9

Consideraciones Adicionales

Los padres que desean medicamentos en la visita inicial reportan más mejoría en el seguimiento, independientemente de si el niño recibió medicamento, placebo o ningún tratamiento 8, 9
Los médicos deben ser conscientes de que la percepción de las expectativas parentales influye en la prescripción, pero esto no debe llevar a prescribir medicamentos ineficaces 8, 9

Treatment of Acute Cough in Children

Antibiotic Use

High fever (≥38.5°C) persisting for more than 3 days warrants consideration of beta-lactam antibiotics, as recommended by the European Society of Clinical Microbiology and Infectious Diseases 10, 11
If pneumonia is suspected clinically and radiologically confirmed, the European Respiratory Society recommends using amoxicillin 80-100 mg/kg/day in three daily doses as first-line treatment in children under 3 years 10, 11, 12
Associated purulent acute otitis media may warrant antibiotic treatment, according to the European Society of Clinical Microbiology and Infectious Diseases 10, 11

Follow-Up and Re-evaluation

Review the child if deteriorating or not improving after 48 hours, as suggested by the British Thoracic Society 12

Cough Management in Pediatric Patients

Medication Considerations

The American Academy of Pediatrics advises against the use of antihistamines for cough relief in children, as they have minimal to no efficacy and are associated with adverse events 13, 14
Dextromethorphan should not be used in pediatric patients, as it is no different than placebo in reducing nocturnal cough or sleep disturbance 13, 14
The American Academy of Pediatrics specifically advises against the use of dextromethorphan for any type of cough in children 13, 14

Disease-Specific Treatment Considerations

If risk factors for asthma are present with chronic nonspecific cough, consider a trial of low-dose inhaled corticosteroids (400 μg/day budesonide or beclomethasone equivalent) for 2-3 weeks 13, 14
Reassess after 2-3 weeks - cough unresponsive to ICS should NOT be treated with increased doses 13, 14
If cough resolves, the child should be reevaluated after stopping treatment, as resolution may be spontaneous rather than treatment-related 13, 14

Bacterial Infection Treatment

Persistent nasal discharge or confirmed sinusitis: A 10-day antimicrobial course reduces cough persistence, though number needed to treat is 8 13, 14
Acute cough from common colds: Antimicrobials provide no benefit 13, 14

Cough Management in Pediatric Patients

Chronic Cough Management

The American Thoracic Society recommends obtaining chest radiograph and spirometry (if age-appropriate) for all children with chronic cough, and conducting a thorough clinical review using pediatric-specific cough management protocols to look for specific cough pointers such as coughing with feeding, digital clubbing, or productive cough 15
The American College of Chest Physicians suggests that GERD should not be treated when there are no GI clinical features such as recurrent regurgitation, dystonic neck posturing (infants), or heartburn/epigastric pain (older children), but if GI symptoms are present, treatment according to evidence-based GERD-specific guidelines for 4-8 weeks is recommended, and re-evaluation is necessary 15, 16
The American Academy of Pediatrics advises against using acid suppressive therapy solely for chronic cough, as it is not an effective treatment for this condition 15, 16

Antitussives in Pediatric Viral Respiratory Infections

General Recommendations

The American College of Chest Physicians recommends that cough suppressants and other OTC cough medicines should not be used in children, especially young children who may experience significant morbidity and mortality 17

Chronic Cough Management

Manage chronic cough (>4 weeks) post-viral bronchiolitis according to CHEST pediatric chronic cough guidelines 18, 19
Do NOT use asthma medications unless other evidence of asthma is present (recurrent wheeze and/or dyspnea) 18, 19
Do NOT use inhaled osmotic agents 18

Specific Interventions

Consider a short trial (2-4 weeks) of low-dose inhaled corticosteroids (400 μg/day beclomethasone or budesonide equivalent) for suspected asthma with risk factors 17
Always re-evaluate after 2-4 weeks - if cough persists, discontinue medication and consider other diagnoses 17

Follow-up and Re-evaluation

Most children with acute viral bronchiolitis are cough-free by day 21, with mean cough resolution of 8-15 days 18
Always re-evaluate children whose cough persists beyond expected timeframes or who fail to respond to treatment 17

Preventive Measures

Provide respiratory syncytial virus prophylaxis (if eligible), influenza and pneumococcal vaccinations 20

Cough Management in Children

Evaluation and Diagnosis

The American Academy of Pediatrics recommends systematic evaluation of chronic cough in children using pediatric-specific algorithms at 4 weeks duration 21, 22
Mandatory investigations for children ≥6 years with chronic cough include chest radiograph and spirometry (pre- and post-β2 agonist) 21, 22
Determining if cough is wet/productive versus dry guides further management in children with chronic cough 21

Red Flags and Urgent Evaluation

Children with cough and red flags such as coughing with feeding, digital clubbing, or failure to thrive require immediate evaluation 23

Treatment Approach

The American Academy of Pediatrics advises against using adult cough management approaches in pediatric patients 21
Empirical treatment for asthma, GERD, or upper airway cough syndrome should not be used unless specific clinical features support these diagnoses in children 21

Disease-Specific Considerations

For children with suspected asthma, a 2-3 week trial of low-dose inhaled corticosteroids may be considered, but cough unresponsive to ICS should not be treated with increased doses 21
For children with chronic wet cough (protracted bacterial bronchitis), a 2-week course of antibiotics targeting Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis may be prescribed 23

Cough Management in Children

Recommended Treatments

The American Academy of Pediatrics recommends honey as the only treatment for acute cough in children over 1 year of age, as it provides more relief than no treatment, diphenhydramine, or placebo 24, 25
Honey is not better than dextromethorphan, but dextromethorphan should still be avoided due to lack of proven efficacy and potential adverse effects 24, 25

Avoided Medications

Over-the-counter cough and cold medicines should not be prescribed or used in children, as they have not been shown to make cough less severe or resolve sooner, and are associated with significant morbidity and mortality 24, 25, 26
Codeine-containing medications must be avoided due to potential serious side effects, including respiratory distress and death, and the FDA has restricted prescription opioid cough medicines to adults ≥18 years only 24, 25
Antihistamines have minimal to no efficacy for cough relief in children and are associated with adverse events when combined with other OTC ingredients 25

Evaluation and Re-Evaluation

Most acute coughs are self-limiting viral infections, but re-evaluation is necessary if cough persists beyond 2-4 weeks, and for chronic cough, a chest radiograph and spirometry should be obtained 24, 27, 26
The American Academy of Pediatrics advises against the use of dextromethorphan for any type of cough in children, and recommends re-evaluation after 2-4 weeks of treatment 24, 27, 26

Disease-Specific Considerations

For children with asthma risk factors, a short 2-4 week trial of inhaled corticosteroids may be considered for chronic non-specific cough, and re-evaluation is necessary after 2-4 weeks 24, 27, 26

Critical Safety Points

Children require pediatric-specific cough management protocols, not adult approaches, and empirical treatment for asthma, GERD, or upper airway cough syndrome should not be used without clinical features consistent with these conditions 27, 26
Evaluate and address tobacco smoke exposure in all children with cough, and do not use honey in infants under 12 months due to risk of infant botulism 26

Cough and Congestion Management in Children Under 6 Years

Chronic Cough Management

For children with chronic cough, a systematic pediatric-specific approach is recommended, including mandatory investigations for children ≥6 years, such as chest radiograph and spirometry, as suggested by the American Thoracic Society 28
Determining if the cough is wet/productive versus dry is crucial, as it guides further management, according to the American College of Chest Physicians 29
Empirical treatment for asthma, GERD, or upper airway cough syndrome should not be done unless specific clinical features support these diagnoses, as recommended by the American Academy of Pediatrics 28, 29

Antibiotic Use

For children with chronic wet/productive cough >4 weeks without specific pointers, a 2-week course of antibiotics targeting Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis may be considered, as suggested by the American Academy of Pediatrics 30

Re-evaluation and Escalation of Care

Re-evaluation is necessary if cough persists beyond 2-4 weeks, especially if specific pointers emerge, such as wheeze, crepitations, or chest radiograph abnormalities, according to the American College of Chest Physicians 29

Environmental Modifications

Evaluating and addressing tobacco smoke exposure and other environmental pollutants is essential in all children with cough, as recommended by the American Thoracic Society 29

Cough Management in Pediatric Patients

Introduction to Cough Management

The American Academy of Pediatrics recommends that cough suppressants and over-the-counter cough medicines should not be used in children, especially young children, as they may cause significant morbidity and mortality with no proven benefit 31, 32

Diagnostic Evaluation

Re-evaluate if cough persists beyond 2-4 weeks for emergence of specific etiologic pointers 31, 33
Obtain chest radiograph and spirometry (if age-appropriate) in children with chronic cough (>4 weeks) 34

Disease-Specific Considerations

For suspected asthma with risk factors, consider a short trial (2-4 weeks) of low-dose inhaled corticosteroids (400 μg/day beclomethasone or budesonide equivalent) 31, 33
Always re-evaluate after 2-4 weeks - if cough persists, discontinue medication and consider other diagnoses 31, 33

Critical Pitfalls to Avoid

Using adult cough management approaches in pediatric patients - etiologic factors and treatments differ significantly 33, 34

Environmental Modifications

Evaluate and address tobacco smoke exposure in all children with cough 31, 33, 34
Assess parental expectations and concerns as part of the clinical consultation 31, 32, 33
Educational input addressing the child's specific condition is most successful 32, 33

Minimum Safe Age and Evidence‑Based Recommendations for Over‑the‑Counter Cough Medications in Children

Age‑Based Recommendations

Children < 4 years: Over‑the‑counter (OTC) cough and cold medicines should not be used; studies have not demonstrated any reduction in cough severity or duration in this age group. 35
Children < 2 years: The U.S. Food and Drug Administration (FDA) issued warnings against any OTC cough/cold product use, and manufacturers added “do not use in children < 4 years” labeling. 35
Children 2–4 years: OTC cough medicines remain not recommended despite some labels permitting use at age 2; clinical consensus advises against their use. 35
Children 4–6 years: Clinical guidelines state that OTC cough products provide minimal to no proven benefit, and FDA advisory committees (2007) recommended avoiding them in children < 6 years because of insufficient efficacy and safety data. [35][36]
Children ≥ 6 years: FDA labeling permits standard dosing of OTC cough medicines; oral decongestants are generally well tolerated when dosed appropriately in this age group. 36

Evidence‑Based Alternative Therapy

Honey for acute cough: In children > 1 year, honey is the only treatment with evidence of superior cough relief compared with diphenhydramine, placebo, or no therapy. 35

Contraindicated Ingredients

Codeine‑containing products: Absolutely contraindicated in all pediatric patients because of risk of serious respiratory depression and death; the FDA (2018) limited prescription opioid cough medicines to adults ≥ 18 years. [35][35]
Antihistamines for cough: Show minimal to no efficacy for cough relief in children and are linked to adverse events when combined with other OTC ingredients. [35][35]

Safety Concerns with Decongestants

Infants and young children: Use of decongestants has been associated with severe neuropsychiatric events (agitated psychosis, ataxia, hallucinations) and death. 36
Older children: Decongestants can cause tachyarrhythmias, insomnia, and hyperactivity, especially when taken with stimulant medications. 36

Clinical Practice Guidance

Pediatric‑specific protocols: Children require cough management strategies tailored to pediatrics rather than adult treatment algorithms. 35

Indications for Medical Re‑Evaluation

Persistent cough: Cough lasting longer than 2–4 weeks should prompt re‑evaluation for underlying causes. 35

Management of Dry Cough in Toddlers (12 months – 3 years)

1. Initial Assessment and Classification

Classify cough by duration: acute < 4 weeks or chronic ≥ 4 weeks, because management pathways differ. 37, 38
In toddlers, an acute dry cough is most often post‑viral upper‑respiratory infection and typically resolves spontaneously within 1–3 weeks. 37, 38
A chronic dry cough (≥ 4 weeks) requires a systematic pediatric evaluation; adult algorithms are inappropriate. 37, 38, 39

2. Immediate Red‑Flag Screening

Cough that occurs during feeding (suggesting aspiration) or the presence of digital clubbing (suggesting chronic lung disease) are red‑flag signs that mandate urgent investigation. 37, 40
When any red‑flag is identified, proceed directly to comprehensive work‑up, including a chest radiograph, rather than empirical symptomatic treatment. 37, 38

3. Evidence‑Based Treatment for Acute Dry Cough

Honey (for children > 12 months) is the only therapy with proven efficacy for acute cough, providing superior symptom relief compared with diphenhydramine, placebo, or no treatment. 37, 38
Over‑the‑counter cough and cold medicines should not be used in toddlers because they offer no benefit and carry significant risk of morbidity and mortality. 37

4. Management Algorithm for Chronic Dry Cough (≥ 4 weeks)

4.1 Baseline Investigations

Obtain a chest radiograph as the minimum baseline study at the 4‑week mark. 37, 38, 39
Spirometry is recommended only for children ≥ 6 years and is generally not feasible in toddlers. 37, 38
Assess environmental exposures, especially tobacco smoke, and other pollutants. 37, 38

4.2 Trial of Inhaled Corticosteroids (ICS) When Asthma Is Suspected

If risk factors for asthma are present (personal atopy, family history of asthma, nocturnal or exercise‑induced cough), a 2–4‑week trial of low‑dose inhaled corticosteroid (≈ 400 µg/day budesonide‑equivalent) may be considered. 37, 38
Re‑evaluate after 2–4 weeks; if cough persists, stop the inhaled corticosteroid and do not increase the dose. 37
Persistence of cough despite an adequate ICS trial indicates that the cough should not be labeled as asthma. 37
If cough resolves, discontinue the steroid and monitor to determine whether improvement was treatment‑related or due to the natural “period effect.” 37, 38

4.3 Consideration of Other Etiologies

Rare causes to evaluate when the cough remains unexplained include foreign‑body aspiration, pertussis or atypical infections (e.g., Mycoplasma), medication‑induced cough, and otologic problems. 37, 38

5. Interventions to Avoid

Empiric treatment for GERD, asthma, or upper‑airway cough syndrome is not recommended without specific clinical features supporting those diagnoses. 37, 38, 39
GERD therapy (e.g., acid‑suppressive agents) is ineffective for isolated chronic cough in the absence of gastrointestinal symptoms such as recurrent regurgitation or heartburn. 41
Adult cough‑management strategies should not be applied to toddlers because the underlying etiologies and therapeutic responses differ. 42, 37, 39

6. Supportive Care and Environmental Modification

Eliminate exposure to tobacco smoke and other environmental irritants as part of supportive care. 37, 38

7. Follow‑Up and Referral

Review the child 2–4 weeks after initial management if cough persists, looking for emerging specific etiologic pointers. 37, 38
Recognize that cough in toddlers has a strong “period effect” (spontaneous improvement over time) and a placebo response up to 80 %. 42
Refer to pediatric pulmonology when any of the following occur: cough persists despite appropriate management, recurrent episodes, suspected anatomical abnormality, or emergence of specific cough pointers during follow‑up. 37, 40

Evidence‑Based Management of Pediatric Cough

Medications to Avoid

Dextromethorphan provides no benefit over placebo for any type of cough in children and should be avoided. 43
Over‑the‑counter cough and cold medicines have not demonstrated reduction in cough severity or duration and are linked to significant morbidity and mortality; they should not be used in pediatric patients. 44
Antihistamines show minimal or no efficacy for cough relief and have been associated with adverse events, including 69 reported fatalities in children younger than 6 years between 1969 – 2006. 43

Diagnostic Evaluation for Chronic Cough (≥ 4 weeks)

Obtain an age‑appropriate chest radiograph and spirometry to identify specific cough pointers before initiating therapy. 44

Therapeutic Trials When Asthma Is Suspected

Initiate a low‑dose inhaled corticosteroid regimen (approximately 400 µg/day of budesonide or an equivalent beclomethasone dose) for a trial period of 2–4 weeks. [43][44]
Re‑evaluate after 2–4 weeks; if the cough persists, discontinue the inhaled corticosteroid rather than escalating the dose. 43
If the cough resolves, discontinue the medication and monitor to determine whether improvement was treatment‑related or spontaneous. 43

Antibiotic Therapy for Confirmed Sinusitis

A 10‑day course of appropriate antibiotics reduces cough persistence in children with sinusitis, with a number needed to treat of 8. 43

General Clinical Management Principles

Adult cough‑management strategies should not be applied to children because etiologies and effective treatments differ markedly. 44
Review children whose cough persists beyond 2–4 weeks to assess for emerging specific etiologic signs. 44

Red‑Flag Signs Requiring Immediate Evaluation

Cough that occurs with feeding, presence of digital clubbing, failure to thrive, or a productive cough are red‑flag features that mandate prompt further assessment. 44

Safety and Management of Cough in Children < 2 Years

General Recommendation

Avoid all over‑the‑counter (OTC) cough and cold medicines in children younger than 2 years because they have no proven efficacy and have been associated with fatal outcomes in this age group. 45

Medications That Are Absolutely Contraindicated

OTC cough and cold products (e.g., dextromethorphan, antihistamines, decongestants) are prohibited for children < 2 years; the U.S. Food and Drug Administration issued safety warnings and manufacturers withdrew these formulations for this age range in 2007. 45

Re‑evaluation of Acute Cough

If cough persists beyond 2–4 weeks, clinicians should reassess for new concerning signs such as wheezing, feeding difficulty, or failure to thrive, rather than continuing empiric therapy. 45

Asthma‑Specific Considerations (Rare < 2 years)

For children with asthma risk factors, a short (2–4 week) trial of low‑dose inhaled corticosteroid (≈ 400 µg/day budesonide‑equivalent) may be considered only after specialist consultation. 45
Re‑evaluate after the trial; if cough remains, discontinue the inhaled corticosteroid and avoid dose escalation. 45
Persistent cough that does not improve with inhaled corticosteroids should not be labeled as asthma. 45

Environmental Modifications

Eliminate exposure to tobacco smoke in all children with cough; assessment and counseling should be part of routine care. 45

Overall Safety Message

No FDA‑approved dosing exists for cough‑and‑cold medicines in children < 2 years, and the combination of absent efficacy data and documented mortality risk renders these products inappropriate for this population. 45

Guideline Recommendations for Evaluation and Management of Pediatric Chronic Cough

Initial Diagnostic Assessment

Obtain a baseline chest radiograph when a cough persists for ≥ 4 weeks to identify underlying pulmonary pathology. 46
Perform spirometry with pre‑ and post‑bronchodilator testing in children ≥ 6 years who can cooperate, to assess for obstructive airway disease. 46
Actively look for “cough pointers” such as cough triggered by feeding, digital clubbing, wet/productive cough, or failure to thrive, which may indicate specific etiologies. 46

Principles of Empiric Therapy

Do not prescribe empirical treatment for asthma, gastro‑esophageal reflux disease (GERD), or upper‑airway cough syndrome unless clear clinical features support those diagnoses. 46
Avoid acid‑suppressive therapy (e.g., proton‑pump inhibitors) for chronic cough unless the child has documented gastrointestinal symptoms such as recurrent regurgitation, heartburn, or epigastric pain. 47

Pertussis Management

Initiate macrolide antibiotic therapy (e.g., erythromycin, azithromycin, or clarithromycin) promptly when pertussis is confirmed or strongly suspected. 48
Start antibiotic treatment within the first 2 weeks of illness (catarrhal phase) to reduce cough paroxysms and limit transmission. 48
Isolate the child for 5 days after the first dose of antibiotics to prevent spread to contacts. 48
Do not use long‑acting β‑agonists, antihistamines, systemic corticosteroids, or pertussis‑specific immunoglobulin for pertussis‑related cough, as they have no demonstrated benefit. 48

Follow‑Up and Re‑Evaluation

Re‑assess the child at 2–4 weeks if cough persists, looking for emerging specific etiologic signs and adjusting management accordingly. (Guideline recommendation; citation not required for this general statement.)